Resonant Capital Advisors LLC Has $2.84 Million Position in Pfizer Inc. $PFE

Resonant Capital Advisors LLC grew its position in Pfizer Inc. (NYSE:PFE) by 5.3% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 117,214 shares of the biopharmaceutical company’s stock after purchasing an additional 5,950 shares during the period. Resonant Capital Advisors LLC’s holdings in Pfizer were worth $2,841,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in PFE. GKV Capital Management Co. Inc. acquired a new position in Pfizer in the first quarter valued at about $27,000. Curio Wealth LLC boosted its holdings in shares of Pfizer by 36,600.0% in the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 1,098 shares in the last quarter. North Capital Inc. bought a new stake in Pfizer during the 1st quarter worth approximately $28,000. Bayforest Capital Ltd acquired a new stake in Pfizer during the 1st quarter valued at $28,000. Finally, Harbor Asset Planning Inc. bought a new position in Pfizer in the 2nd quarter valued at $29,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

PFE opened at $24.79 on Friday. The company has a fifty day moving average price of $24.87 and a two-hundred day moving average price of $24.18. The firm has a market capitalization of $140.92 billion, a PE ratio of 13.18, a P/E/G ratio of 0.82 and a beta of 0.55. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $29.17. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm’s revenue was up 10.3% on a year-over-year basis. During the same period last year, the company earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. The ex-dividend date is Friday, November 7th. Pfizer’s dividend payout ratio (DPR) is currently 91.49%.

Wall Street Analyst Weigh In

Several brokerages have recently commented on PFE. Bank of America increased their target price on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Morgan Stanley lowered their price objective on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research report on Friday, October 10th. Citigroup upped their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a report on Saturday. Finally, Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $28.13.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.